<p>Vera Therapeutics（納斯達克代碼：VERA - 獲取免費報告）於週四發佈了其財報。公司報告本季度每股收益（EPS）為（$1.69），低於市場共識預期的（$1.33），差距為（$0.36），Briefing.com 報道稱。在去年同期，公司每股收益為（$0.81）。</p>
<p>獲取 <strong>Vera Therapeutics</strong> 的提醒：</p>
<h2>Vera Therapeutics 股票表現</h2>
<ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
<p>週四午盤交易中，納斯達克代碼：VERA 的股票下跌 $0.72，報 $35.88。該公司的交易量為 972,545 股，而其平均交易量為 1,190,760 股。公司的 50 日移動平均價格為 $39.96，200 日移動平均價格為 $40.35。公司的流動比率為 13.64，速動比率為 13.64，債務股本比率為 0.12。該股票的市值為 25.6 億美元，市盈率為 -7.70，貝塔值為 0.96。Vera Therapeutics 的 52 周低點為 $18.76，52 周高點為 $56.05。</p>
<h2>分析師評級上調與下調</h2>
<p>幾家研究機構最近對 VERA 發佈了報告。HC Wainwright 將 Vera Therapeutics 的目標價格從 $90.00 上調至 $110.00，並在 3 月 2 日的研究報告中給予該股票 “買入” 評級。Wolfe Research 將 Vera Therapeutics 的評級從 “同行表現” 上調至 “跑贏大盤”，並在 3 月 11 日的報告中設定了 $88.00 的目標價格。最後，Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Vera Therapeutics 的 “賣出（d-）” 評級。十位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為 $79.60。</p>
<p><strong>查看我們關於 VERA 的最新研究報告</strong></p>
<h2>內部人士買賣情況</h2>
<p>在相關消息中，首席運營官 David Lee Johnson 於 2 月 23 日星期一出售了 2,579 股公司的股票。股票以平均價格 $41.98 出售，總價值為 $108,266.42。交易後，首席運營官直接持有 45,727 股公司的股票，價值約為 $1,919,619.46。此次交易使其持股減少了 5.34%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，高級副總裁 Joseph R. Young 於 2 月 23 日星期一出售了 3,117 股公司的股票。股票以平均價格 $41.98 出售，總交易額為 $130,851.66。出售後，高級副總裁直接持有 64,722 股公司的股票，價值約為 $2,717,029.56。此次交易使其持股減少了 4.59%。該出售的 SEC 備案提供了更多信息。在過去九十天內，內部人士出售了價值 $2,416,902 的 56,441 股公司股票。公司內部人士持有 15.90% 的公司股票。</p>
<h2>機構投資者對 Vera Therapeutics 的看法</h2>
<p>幾家機構投資者最近增加或減少了對 VERA 的持股。洛杉磯資本管理公司在第四季度購買了價值約 $46,000 的 Vera Therapeutics 新股份。Quantbot Technologies LP 在第二季度購買了價值約 $51,000 的 Vera Therapeutics 新股份。Aster Capital Management DIFC Ltd 在第四季度購買了價值約 $71,000 的 Vera Therapeutics 新股份。Tower Research Capital LLC TRC 在第二季度將其在 Vera Therapeutics 的持股增加了 192.9%。Tower Research Capital LLC TRC 現在擁有 4,186 股公司的股票，價值 $99,000，此前在該期間又購買了 2,757 股。最後，Sandia Investment Management LP 在第四季度購買了價值約 $127,000 的 Vera Therapeutics 新股份。99.21% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Vera Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Vera Therapeutics 是一家臨牀階段的生物技術公司，專注於開發新型免疫療法，利用身體自身的調節性 T 細胞治療自身免疫和炎症性疾病。通過利用專有的蛋白質工程平台，公司設計了選擇性針對 Treg 的細胞因子變體，旨在恢復免疫平衡並提供針對性的、改變疾病進程的效果。其產品管線包括多個針對慢性炎症和自身免疫特徵的臨牀前和臨牀候選藥物。</p>
<p>Vera Therapeutics 成立於 2018 年，總部位於馬薩諸塞州劍橋，與領先的學術和研究機構合作，推動其開發項目。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Vera Therapeutics 嗎？</h2>
<p>在考慮投資 Vera Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Vera Therapeutics 並不在名單上。</p>
<p>雖然 Vera Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VERA

標普生物技術 3 倍做空 - Direxion

IBBQ

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

<p>Vera Therapeutics（納斯達克代碼：VERA）報告的季度每股收益為（$1.69），低於市場共識預期的（$1.33），差距為（$0.36）。這比去年同期的每股收益（$0.81）有所下降。該股交易下跌至$35.88，市值為$25.6 億。分析師的評級意見不一，市場共識評級為 “適度買入”，平均目標價為$79.60。近期注意到內部人士的股票出售和機構投資，企業內部人士持有該股票的 15.90%</p>

<p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) posted its earnings results on Thursday. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36), Briefing.com reports. During the same period in the previous year, the company posted ($0.81) EPS.</p>
<div class="lb-trans"><p>Vera Therapeutics（納斯達克代碼：VERA - 獲取免費報告）於週四發佈了其財報。公司報告本季度每股收益（EPS）為（$1.69），低於市場共識預期的（$1.33），差距為（$0.36），Briefing.com 報道稱。在去年同期，公司每股收益為（$0.81）。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vera Therapeutics</strong> 的提醒：</p>
</div><h2>Vera Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票表現</h2>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
</div><p>Shares of NASDAQ:VERA traded down $0.72 during midday trading on Thursday, reaching $35.88. The company had a trading volume of 972,545 shares, compared to its average volume of 1,190,760. The company's 50 day moving average price is $39.96 and its 200 day moving average price is $40.35. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. The stock has a market cap of $2.56 billion, a P/E ratio of -7.70 and a beta of 0.96. Vera Therapeutics has a 52-week low of $18.76 and a 52-week high of $56.05.</p>
<div class="lb-trans"><p>週四午盤交易中，納斯達克代碼：VERA 的股票下跌 $0.72，報 $35.88。該公司的交易量為 972,545 股，而其平均交易量為 1,190,760 股。公司的 50 日移動平均價格為 $39.96，200 日移動平均價格為 $40.35。公司的流動比率為 13.64，速動比率為 13.64，債務股本比率為 0.12。該股票的市值為 25.6 億美元，市盈率為 -7.70，貝塔值為 0.96。Vera Therapeutics 的 52 周低點為 $18.76，52 周高點為 $56.05。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Several research firms have recently issued reports on VERA. HC Wainwright upped their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, March 2nd. Wolfe Research raised shares of Vera Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $88.00 price target on the stock in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $79.60.</p>
<div class="lb-trans"><p>幾家研究機構最近對 VERA 發佈了報告。HC Wainwright 將 Vera Therapeutics 的目標價格從 $90.00 上調至 $110.00，並在 3 月 2 日的研究報告中給予該股票 “買入” 評級。Wolfe Research 將 Vera Therapeutics 的評級從 “同行表現” 上調至 “跑贏大盤”，並在 3 月 11 日的報告中設定了 $88.00 的目標價格。最後，Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Vera Therapeutics 的 “賣出（d-）” 評級。十位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為 $79.60。</p>
</div><p><strong>Check Out Our Latest Research Report on VERA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 VERA 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In related news, COO David Lee Johnson sold 2,579 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $108,266.42. Following the transaction, the chief operating officer directly owned 45,727 shares of the company's stock, valued at approximately $1,919,619.46. The trade was a 5.34% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 3,117 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $130,851.66. Following the sale, the senior vice president directly owned 64,722 shares in the company, valued at approximately $2,717,029.56. This trade represents a 4.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 56,441 shares of company stock worth $2,416,902 in the last ninety days. Corporate insiders own 15.90% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席運營官 David Lee Johnson 於 2 月 23 日星期一出售了 2,579 股公司的股票。股票以平均價格 $41.98 出售，總價值為 $108,266.42。交易後，首席運營官直接持有 45,727 股公司的股票，價值約為 $1,919,619.46。此次交易使其持股減少了 5.34%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，高級副總裁 Joseph R. Young 於 2 月 23 日星期一出售了 3,117 股公司的股票。股票以平均價格 $41.98 出售，總交易額為 $130,851.66。出售後，高級副總裁直接持有 64,722 股公司的股票，價值約為 $2,717,029.56。此次交易使其持股減少了 4.59%。該出售的 SEC 備案提供了更多信息。在過去九十天內，內部人士出售了價值 $2,416,902 的 56,441 股公司股票。公司內部人士持有 15.90% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Vera Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Vera Therapeutics 的看法</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in VERA. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP bought a new stake in shares of Vera Therapeutics during the second quarter valued at about $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at about $71,000. Tower Research Capital LLC TRC increased its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after buying an additional 2,757 shares during the period. Finally, Sandia Investment Management LP bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at about $127,000. 99.21% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近增加或減少了對 VERA 的持股。洛杉磯資本管理公司在第四季度購買了價值約 $46,000 的 Vera Therapeutics 新股份。Quantbot Technologies LP 在第二季度購買了價值約 $51,000 的 Vera Therapeutics 新股份。Aster Capital Management DIFC Ltd 在第四季度購買了價值約 $71,000 的 Vera Therapeutics 新股份。Tower Research Capital LLC TRC 在第二季度將其在 Vera Therapeutics 的持股增加了 192.9%。Tower Research Capital LLC TRC 現在擁有 4,186 股公司的股票，價值 $99,000，此前在該期間又購買了 2,757 股。最後，Sandia Investment Management LP 在第四季度購買了價值約 $127,000 的 Vera Therapeutics 新股份。99.21% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Vera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Vera Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.</p>
<div class="lb-trans"><p>Vera Therapeutics 是一家臨牀階段的生物技術公司，專注於開發新型免疫療法，利用身體自身的調節性 T 細胞治療自身免疫和炎症性疾病。通過利用專有的蛋白質工程平台，公司設計了選擇性針對 Treg 的細胞因子變體，旨在恢復免疫平衡並提供針對性的、改變疾病進程的效果。其產品管線包括多個針對慢性炎症和自身免疫特徵的臨牀前和臨牀候選藥物。</p>
</div><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p>
<div class="lb-trans"><p>Vera Therapeutics 成立於 2018 年，總部位於馬薩諸塞州劍橋，與領先的學術和研究機構合作，推動其開發項目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Vera Therapeutics 嗎？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Vera Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Vera Therapeutics 並不在名單上。</p>
</div><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vera Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.36 EPS

Market Beat

Vera Therapeutics

Invesco Nasdaq Biotechnology ETF

Vera Therapeutics（NASDAQ:VERA）公佈季度財報，每股收益比預期低 0.36 美元